Trial Profile

A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cat SPIRE (Primary)
Indications Allergic rhinoconjunctivitis; Perennial allergic rhinitis
Focus Registrational; Therapeutic Use
Acronyms CATALYST
Sponsors Circassia; Niox

Most Recent Events

25 Jul 2016 Status changed from active, no longer recruiting to completed.
22 Apr 2016 The trial was prematurely ended in Lithuania, Latvia and Estonia; completed in Poland (end date: 2016-02-02).
06 Jun 2015 Planned number of patients changed from 1182 to 1400, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com